This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements use words, and variations of words, such as "will," "expect," "next," "project," "potential," "continue," "expand" and "grow" in discussions of topics such as strategy for growth and expectations for future product development, regulatory approvals and market position. Forward-looking statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections in this presentation and accompanying remarks. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; changes to governmental laws and regulations; domestic and foreign health care reforms including trends toward health care cost containment; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statements as a result of new information or future events or developments.